2022 NCI Alliance for Nanotechnology in Cancer Annual Principal Investigator Meeting (Archive)

Submitted by nusratyj on Thu, 03/23/2023 - 12:10
-
2022 NCI Alliance for Nanotechnology in Cancer Annual Principal Investigator Meeting
NCI Alliance for Nanotechnology in Cancer Annual Principal Investigator Meeting
 
October 18-19, 2022
 
Virtual

Meeting Summary

The 2022 NCI Alliance for Nanotechnology in Cancer Annual Principal Investigator Meeting will be held virtually on October 18-19, 2022. The meeting will gather the Alliance investigators and collaborators to present their recent research results as well as to discuss emerging opportunities in cancer nanotechnology. This year the scientific sessions will include: Cancer interventions enabled by new material designs; Novel cancer therapies based on nanotechnology; and Immunotherapies and vaccines. This year’s meeting will also feature panel discussions on topics “What will be the next nano-drug approved by FDA?” and “Can nanotechnology aid in combating cancer metastasis?”. 

 

Agenda

 

DAY 1: October 18, 2022

9:00 am – 10:00 am

Join Meeting – Computer Check

10:00 am – 10:20 am

Welcome and Introduction
Janet Eary, M.D., Associate Director, CANCER IMAGING PROGRAM (CIP), DCTD, NCI
Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI

10:20 am – 11:00 am

Plenary presentation
Molly S Shoichet, Ph.D., UNIVERSITY OF TORONTO

SESSION I: CANCER INTERVENTIONS ENABLED BY NEW MATERIAL DESIGNS (PART 1)
MODERATOR: Piotr Grodzinski , Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI
11:00 am – 11:20 am

The tumor microenvironment in nanoparticle delivery and function
Zaver, Bhujwalla, Ph.D., JOHNS HOPKINS UNIVERSITY

11:20 am – 11:40 am

Imaging of nanotherapeutic drug action
Presented by Miles Miller, Ph.D., MASSACHUSETTS GENERAL HOSPITAL
(PI Ralph Weissleder, M.D., Ph.D., MASSACHUSETTS GENERAL HOSPITAL)

11:40 am – 12:00 pm

Copper-depleting nanotheranostics for treating triple negative breast cancer
Jianghong Rao, Ph.D., STANFORD UNIVERSITY

12:00 pm – 12:20 pm

In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy
Konstantin Sokolov, Ph.D., UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

12:20 pm – 12:40 pm

Fluorescent indocarbocyanine PEGylated lipid nanoparticles for understanding and
overcoming barriers to drug delivery in invasive glioblastoma

Dmitri Simberg, Ph.D., UNIVERSITY OF COLORADO DENVER

12:40 pm – 1:10 pm

LUNCH BREAK

Session II. Discussion Panel: WHAT WILL BE THE NEXT NANO-DRUG APPROVED BY FDA?
Moderator: Andrew Wang, M.D., UT SOUTHWESTERN MEDICAL CENTER
1:10 pm – 2:10 pm

Panel:

  1. Andre Nel, M.D., Ph.D., UNIVERSITY OF CALIFORNIA, LOS ANGELES
  2. Aleks Radovic-Moreno, Ph.D., LONGWOOD FUND
  3. Stephan Stern, Ph.D., DABT, NANOTECHNOLOGY CHARACTERIZATION LABORATORY
SESSION III: NOVEL CANCER THERAPIES BASED ON NANOTECHNOLOGY
MODERATOR: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
2:10 pm - 2:30 pm

Ultrasmall particle-based solutions for inducing ferroptosis and improving antitumor immune responses in cancer
Michelle Bradbury, M.D., Ph.D., MEMORIAL SLOAN KETTERING CANCER CENTER

2:30 pm - 2:50 pm

Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
Lily Yang, M.D., Ph.D., EMORY UNIVERSITY

2:50 pm - 3:10 pm

Nanodelivery platform for antibody drugs targeting NHL
Masakazu Kamata, Ph.D., UNIVERSITY OF ALABAMA AT BIRMINGHAM

3:10 pm - 3:30 pm

Towards translation of MU-CN29: New therapeutic nanoparticle for drug resistant NSCLC
Raghuramann Kannan, M.D., UNIVERSITY OF MISSOURI-COLUMBIA

3:30 pm – 3:45 pm

BREAK

3:45 pm - 4:05 pm

Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling
Gabriel Lopez-Berestein, M.D., UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

4:05 pm - 4:25 pm

TNBC ligand-displaying exosomes using RNA nanotechnology for targeted cytosol delivery of RNAi without endosome entrapment
Presented by Daniel Binzel, Ph.D., OHIO STATE UNIVERSITY (MPI)
(PI Dan Shu, M.D., OHIO STATE UNIVERSITY)

4:25 pm - 4:45 pm

Novel approach to attenuate small cell lung cancer growth and metastasis
Mohd Wasim Nasser, Ph.D., UNIVERSITY OF NEBRASKA MEDICAL CENTER

4:45 pm - 5:00 pm

Q&A/Day 1 Wrap-up
Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI

DAY 2: October 19, 2022

9:00 am - 10:00 am

Join Meeting-Computer Check

10:00 am - 10:10 am

Day 1 recap

SESSION IV: CANCER INTERVENTIONS ENABLED BY NEW MATERIAL DESIGNS (PART 2)
MODERATOR: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
10:10 am - 10:30 am

Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
Jin Xie, Ph.D., UNIVERSITY OF GEORGIA

10:30 am - 10:50 am

The development of novel radiation-sensitizer based on ultra-small carbon dots
Zibo Li , Ph.D., UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL

10:50 am - 11:10 am

Stimuli-responsive mucin1-specific nanoparticles for efficacious combinatorial
chemotherapy of pancreatic ductal adenocarcinoma

Juan Luis Vivero-Escoto, Ph.D., UNIVERSITY OF NORTH CAROLINA, CHARLOTTE

11:10 am - 11:30 am

Nanotechnology for targeted therapy and fundamental understanding of
therapeutic resistance in triple negative breast cancer

Xiaoming He, Ph.D., UNIVERSITY OF MARYLAND, COLLEGE PARK

11:30 am - 11:50 am

Map leukemia-immune cell talks with nanoplasmon ruler in CAR T-cell immunotherapy
Presented by Pengyu Chen, Ph.D., AUBURN UNIVERSITY (MPI)
(PI Weiqiang Chen, Ph.D., NEW YORK UNIVERSITY)

11:50 am - 12:20 pm

LUNCH BREAK

SESSION V: PANEL DISCUSSION: CAN NANOTECHNOLOGY AID IN COMBATING CANCER METASTASIS?
Moderator: Patricia Steeg, Ph.D., CENTER FOR CANCER RESEARCH, NCI
12:20 pm - 1:20 pm

PANEL:

  1. Hannah Linden, M.D., F.A.C.P, FRED HUTCHINSON CANCER RESEARCH CENTER
  2. Wasim Nasser, Ph.D., UNIVERSITY OF NEBRASKA MEDICAL CENTER
  3. Baran Sumer, M.D., F.A.C.S., UT SOUTHWESTERN MEDICAL CENTER
SESSION VI: IMMUNOTHERAPIES AND VACCINES
MODERATOR: Leela Rani Avula, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
1:20 pm – 1:40 pm

A cobalt porphyrin nanoliposome adjuvant for MHC-I-restricted cancer peptide vaccines
Jonathan Lovell, Ph.D., STATE UNIVERSITY OF NEW YORK AT BUFFALO

1:40 pm – 2:00 pm

Innovative research for cancer nanotechnology (IRCN) for enhancing melanoma-
specific immune responses by the rational design of spherical nucleic acids

Presented by Bin Zhang, M.D., Ph.D., NORTHWESTERN UNIVERSITY (MPI)
(PI Chad Mirkin, Ph.D., NORTHWESTERN UNIVERSITY)

2:00 pm – 2:20 pm

Targeting effector immune cells to cancer with chemically self-assembled nanorings (CSANs)
Carston Wagner, Ph.D., UNIVERSITY OF MINNESOTA

2:20 pm - 2:40 pm

BREAK

2:40 pm – 3:00 pm

Toward translation of an immunotherapeutic nanomedicine for neuroblastoma
John Tanner Wilson, Ph.D., VANDERBILT UNIVERSITY

3:00 pm – 3:20 pm

Whitlockite nanoparticle-based immunotherapy for bone metastasis
Presented by Hae Lin Jang, Ph.D., BRIGHAM AND WOMEN'S HOSPITAL (MPI)
(PI Shiladitya Sengupta, Ph.D., BRIGHAM AND WOMEN'S HOSPITAL)

3:20 pm – 3:40 pm

Toward translation of a plant virus-based in situ vaccination nanotechnology
Nicole Franziska Steinmetz, Ph.D., UNIVERSITY OF CALIFORNIA, SAN DIEGO

3:40 pm- 4:00 pm

Closing Remarks
Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI